We also observed a further recovery and normalization of platelet levels in the combination-treated mice, suggesting that sustained stimulation of platelet production can ameliorate the risk of thrombocytopenia from continuous BCL-XL inhibition. This evidence concerns the gene BCL2L1 and Thrombocytopenia.